Regenerative Medical Solutions has received approval from the Wisconsin Economic Development Corporation (WEDC) for a 25% state income tax credit for qualified investors.
This incentive offers Wisconsin-based investors a compelling opportunity: for every dollar invested in RMS, they may receive 25 cents back as a state income tax credit. The move not only supports economic development in Wisconsin but also advances one of the most promising developments in diabetes treatment today.
A Pioneering Approach to Diabetes Treatment
RMS is developing a therapy that uses human-induced pluripotent stem cells (iPSCs) to create islet-like clusters (ILCs), a potential game-changer for diabetes care. These clusters are designed to mimic the function of pancreatic islets, restoring insulin production and regulating blood sugar levels in people with Type 1 and Type 2 diabetes.
Unlike current therapies that rely on insulin injections or organ transplants, RMS’s approach eliminates the need for organ donors and immunosuppressive drugs, which often come with serious side effects.
“Our mission is to deliver a safe, regenerative cell therapy that transforms the lives of diabetes patients worldwide,” said Anthony Kolton, CEO of RMS. “With the WEDC’s support, Wisconsin investors have a unique opportunity to not only impact public health but also benefit financially from their involvement. This 25% tax credit is a powerful incentive for those who want to support groundbreaking innovation close to home.”
An Opportunity for Visionary Investors
As diabetes continues to affect millions of people across the U.S., the demand for a more effective and lasting treatment grows stronger. RMS’s non-embryonic, stem cell-based therapy offers new hope for patients and a strong investment opportunity for those ready to help bring it to market.
Learn more about the tax credit and request a prospectus for investing.